1
|
Chen JW, Jacot W, Cortés J, Krop IE, Dent S, Harbeck N, De Laurentiis M, Diéras V, Im Y, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Mol Oncol 2023; 17:2000-2016. [PMID: 36892268 PMCID: PMC10552898 DOI: 10.1002/1878-0261.13416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 02/10/2023] [Accepted: 03/07/2023] [Indexed: 03/10/2023] Open
Abstract
Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with response to PI3K inhibition, we analysed circulating tumour DNA (ctDNA) from participants enrolled in the SANDPIPER trial. Participants were designated as either PIK3CAmut or PIK3CA no mutation was detected (NMD) per baseline ctDNA. The top mutated genes and tumour fraction estimates identified were analysed for their association with outcomes. In participants with PIK3CAmut ctDNA treated with taselisib + fulvestrant, tumour protein p53 (TP53; encoding p53) and fibroblast growth factor receptor 1 (FGFR1) alterations were associated with shorter progression-free survival (PFS) compared to participants with NMD in these genes. Conversely, participants with PIK3CAmut ctDNA harbouring a neurofibromin 1 (NF1) alteration or high baseline tumour fraction estimate experienced improved PFS upon treatment with taselisib + fulvestrant compared to placebo + fulvestrant. Broadly, alterations in oestrogen receptor (ER), PI3K and p53 pathway genes were associated with resistance to taselisib + fulvestrant in participants with PIK3CAmut ctDNA. Altogether, we demonstrated the impact of genomic (co-)alterations on outcomes with one of the largest clinico-genomic datasets of ER+, HER2-, PIK3CAmut breast cancer patients treated with a PI3K inhibitor.
Collapse
Affiliation(s)
- Jessica W. Chen
- Oncology Biomarker DevelopmentGenentech, Inc.South San FranciscoCAUSA
| | - William Jacot
- Institut du Cancer de Montpellier (ICM) Val d'AurelleMontpellier University, INSERM U1194France
| | - Javier Cortés
- International Breast Cancer Center (IBCC), Pangaea OncologyQuironsalud GroupMadridSpain
- International Breast Cancer Center (IBCC), Pangaea OncologyQuironsalud GroupBarcelonaSpain
- Faculty of Biomedical and Health Sciences, Department of MedicineUniversidad Europea de MadridMadridSpain
| | | | - Susan Dent
- Duke Cancer InstituteDuke UniversityDurhamNCUSA
| | - Nadia Harbeck
- Breast Center, Department Gynecology and Obstetrics and Comprehensive Cancer Center (CCC) MunichLudwig‐Maximilians‐University (LMU) HospitalMunichGermany
| | | | | | - Young‐Hyuck Im
- Division of Hematology‐Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
| | - Thomas J. Stout
- Product Development OncologyGenentech, Inc.South San FranciscoCAUSA
| | | | - Heidi M. Savage
- Oncology Biomarker DevelopmentGenentech, Inc.South San FranciscoCAUSA
| | | | - Timothy R. Wilson
- Oncology Biomarker DevelopmentGenentech, Inc.South San FranciscoCAUSA
| |
Collapse
|
2
|
Hutchinson KE, Chen JW, Savage HM, Stout TJ, Schimmoller F, Cortés J, Dent S, Harbeck N, Jacot W, Krop I, Trabucco SE, Sivakumar S, Sokol ES, Wilson TR. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. Genome Med 2023; 15:28. [PMID: 37101291 PMCID: PMC10131374 DOI: 10.1186/s13073-023-01181-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Accepted: 04/14/2023] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35-40% of patients with HR+/HER2- breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut) elicit hyperactivation of the PI3K pathway leading to enhanced sensitivity to p110α inhibitors. METHODS To understand the role of multiple PIK3CAmut in predicting response to p110α inhibition, we estimated the clonality of multiple PIK3CAmut in circulating tumor DNA (ctDNA) from patients with HR+/HER2- metastatic breast cancer enrolled to a prospectively registered clinical trial of fulvestrant ± taselisib, and analyzed the subgroups against co-altered genes, pathways, and outcomes. RESULTS ctDNA samples with clonal multiple PIK3CAmut had fewer co-alterations in receptor tyrosine kinase (RTK) or non-PIK3CA PI3K pathway genes compared to samples with subclonal multiple PIK3CAmut indicating a strong reliance on the PI3K pathway. This was validated in an independent cohort of breast cancer tumor specimens that underwent comprehensive genomic profiling. Furthermore, patients whose ctDNA harbored clonal multiple PIK3CAmut exhibited a significantly higher response rate and longer progression-free survival vs subclonal multiple PIK3CAmut. CONCLUSIONS Our study establishes clonal multiple PIK3CAmut as an important molecular determinant of response to p110α inhibition and provides rationale for further clinical investigation of p110α inhibitors alone or with rationally-selected therapies in breast cancer and potentially other solid tumor types.
Collapse
Affiliation(s)
- Katherine E Hutchinson
- Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Jessica W Chen
- Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Heidi M Savage
- Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Thomas J Stout
- Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA
| | - Frauke Schimmoller
- Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA
| | - Javier Cortés
- International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid & Barcelona, Spain
- Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain
| | - Susan Dent
- Duke Cancer Institute, Duke University, Durham, NC, USA
| | - Nadia Harbeck
- Breast Center, Department Gynecology and Obstetrics and Comprehensive Cancer Center (CCC) Munich, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany
| | - William Jacot
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, Montpellier, France
| | - Ian Krop
- Yale Cancer Center, New Haven, CT, USA
| | | | | | | | - Timothy R Wilson
- Oncology Biomarker Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
| |
Collapse
|
3
|
Chen JW, Murugesan K, Newberg JY, Sokol ES, Savage HM, Stout TJ, Maund SL, Hutchinson KE. Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. JCO Precis Oncol 2022; 6:e2200341. [PMID: 36446041 PMCID: PMC9812634 DOI: 10.1200/po.22.00341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
PURPOSE Understanding the differences in biomarker prevalence that may exist among diverse populations is invaluable to accurately forecast biomarker-driven clinical trial enrollment metrics and to advance inclusive research and health equity. This study evaluated the frequency and types of PIK3CA mutations (PIK3CAmut) detected in predicted genetic ancestry subgroups across breast cancer (BC) subtypes. METHODS Analyses were conducted using real-world genomic data from adult patients with BC treated in an academic or community setting in the United States and whose tumor tissue was submitted for comprehensive genomic profiling. RESULTS Of 36,151 patients with BC (median age, 58 years; 99% female), the breakdown by predicted genetic ancestry was 75% European, 14% African, 6% Central/South American, 3% East Asian, and 1% South Asian. We demonstrated that patients of African ancestry are less likely to have tumors that harbor PIK3CAmut compared with patients of European ancestry with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) BC (37% [949/2,593] v 44% [7,706/17,637]; q = 4.39E-11) and triple-negative breast cancer (8% [179/2,199] v 14% [991/7,072]; q = 6.07E-13). Moreover, we found that PIK3CAmut were predominantly composed of hotspot mutations, of which mutations at H1047 were the most prevalent across BC subtypes (35%-41% ER+/HER2- BC; 43%-61% HER2+ BC; 40%-59% triple-negative breast cancer). CONCLUSION This analysis established that tumor PIK3CAmut prevalence can differ among predicted genetic ancestries across BC subtypes on the basis of the largest comprehensive genomic profiling data set of patients with cancer treated in the United States. This study highlights the need for equitable representation in research studies, which is imperative to ensuring better health outcomes for all.
Collapse
Affiliation(s)
- Jessica W. Chen
- Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA
| | | | | | - Ethan S. Sokol
- Cancer Genomics Research, Foundation Medicine, Inc, Cambridge, MA
| | - Heidi M. Savage
- Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA
| | - Thomas J. Stout
- Product Development Oncology, Genentech, Inc, South San Francisco, CA
| | - Sophia L. Maund
- Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA
| | - Katherine E. Hutchinson
- Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA,Katherine E. Hutchinson, PhD, Oncology Biomarker Development, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080; Twitter: @genentech; e-mail:
| |
Collapse
|
4
|
Diegmiller R, Salphati L, Alicke B, Wilson TR, Stout TJ, Hafner M. Growth‐rate model predicts in vivo tumor response from in vitro data. CPT Pharmacometrics Syst Pharmacol 2022; 11:1183-1193. [PMID: 35731938 PMCID: PMC9469692 DOI: 10.1002/psp4.12836] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 05/18/2022] [Accepted: 06/07/2022] [Indexed: 11/18/2022] Open
Abstract
A major challenge in oncology drug development is to elucidate why drugs that show promising results in cancer cell lines in vitro fail in mouse studies or human trials. One of the fundamental steps toward solving this problem is to better predict how in vitro potency translates into in vivo efficacy. A common approach to infer whether a model will respond in vivo is based on in vitro half‐maximal inhibitory concentration values (IC50), but yields limited quantitative comparison between cell lines and drugs, potentially because cell division and death rates differ between cell lines and in vivo models. Other methods based either on mechanistic modeling or machine learning require molecular insights or extensive training data, limiting their use for early drug development. To address these challenges, we propose a mathematical model integrating in vitro growth rate inhibition values with pharmacokinetic parameters to estimate in vivo drug response. Upon calibration with a drug‐specific factor, our model yields precise estimates of tumor growth rate inhibition for in vivo studies based on in vitro data. We then demonstrate how our model can be used to study dosing schedules and perform sensitivity analyses. In addition, it provides meaningful metrics to assess association with genotypes and guide clinical trial design. By relying on commonly collected data, our approach shows great promise for optimizing drug development, better characterizing the efficacy of novel molecules targeting proliferation, and identifying more robust biomarkers of sensitivity while limiting the number of in vivo experiments.
Collapse
Affiliation(s)
- Rocky Diegmiller
- Department of Chemical and Biological Engineering and Lewis‐Sigler Institute for Integrative Genomics Princeton University Princeton New Jersey USA
| | - Laurent Salphati
- Department of Drug Metabolism and Pharmacokinetics Genentech Inc. South San Francisco California USA
| | - Bruno Alicke
- Department of Translational Oncology Genentech Inc. South San Francisco California USA
| | - Timothy R. Wilson
- Department of Oncology Biomarker Development Genentech Inc. South San Francisco California USA
| | - Thomas J. Stout
- Department of Product Development Oncology Genentech Inc. South San Francisco California USA
| | - Marc Hafner
- Department of Oncology Bioinformatics Genentech Inc. South San Francisco California USA
| |
Collapse
|
5
|
Chen JW, Dent S, Jacot W, Cortés J, Krop IE, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR. Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mutations in PIK3CA, encoding the catalytic subunit p110α of PI3K, are present in ~40% of ER+/HER- BC. Taselisib (TAS) is a potent and selective β-sparing PI3K inhibitor that improves outcomes in combination with endocrine therapy in pts with PIK3CAmut advanced breast cancer (aBC). To better understand the molecular alterations associated with response to PI3K inhibition, we profiled the genomic landscape of ctDNA collected from PIK3CAmut, ER+, HER2- aBC pts immediately prior to treatment (tx) with TAS or placebo (PBO) plus fulvestrant (FUL).
Methods: Pts were enrolled as part of a phase III randomized study of TAS or PBO plus FUL in ER+, HER2- PIK3CAmut aBC (SANDPIPER, NCT02340221). Pre-tx ctDNA samples from 508 pts underwent comprehensive genomic profiling using the FoundationOne Liquid NGS assay at Foundation Medicine, Inc.; the 339 pts with PIK3CAmut ctDNA were further analyzed herein. The top mutated genes were analyzed for prognostic value against investigator-assessed progression-free survival (PFS) for both tx regimens using Cox proportional hazards regression modeling. As analysis was exploratory, no adjustments were made for multiple testing.
Results: The top altered genes were TP53 (44%), ESR1 (37%), CDH1 (17%), FGFR1 (12%), NF1 (11%), CHEK2 (10%), and PTEN (9%). In pts treated with PBO+FUL, alterations in PTEN (HR 2.8; 95% CI 1.4-5.7; p=0.0107) and TP53 (HR 2.0; 95% CI 1.3-3.1; p=0.0025) were associated with a worse prognosis compared to pts with no mutation detected (NMD) in these genes. In pts treated with TAS+FUL, alterations in FGFR1 (HR 2.4; 95% CI 1.5-3.7; p=0.0006), TP53 (HR 1.9; 95% CI 1.4-2.6; p=0.0001) and PTEN (HR 1.8; 95% CI 1.1-2.8; p=0.0265) were associated with a worse prognosis compared to pts with NMD in these genes. Alterations in ESR1, CDH1, or CHEK2 were not associated with prognosis (p≥0.05) in either tx arm. A trend towards worse prognosis was observed in pts with NF1 altered ctDNA treated with PBO+FUL (HR 2.1; 95% CI 1.1-4.1; p=0.0527), which was not observed in pts treated with TAS+FUL (HR 0.97; 95% CI 0.57-1.65; p=0.901). Within the NF1-altered subgroup, a significant PFS difference was observed between TAS- vs PBO-treated pts (HR 0.28; 95% CI 0.11-0.67; p=0.0058; median 5.65 vs 1.94 months, respectively).
Conclusions: We report that the most frequently mutated genes identified are consistent with previous studies in pts with ER+, HER2- aBC. This analysis shows that alterations in TP53 and PTEN were associated with poor prognosis in both tx arms, and FGFR1 alterations were associated with a poor prognosis in TAS+FUL treated pts. Further, NF1 alterations were associated with a poor prognosis in PBO+FUL treated pts, an association that was not observed with TAS+FUL. These findings may inform future rational combination strategies for the clinical development of PI3K inhibitors.
Citation Format: Jessica W. Chen, Susan Dent, William Jacot, Javier Cortés, Ian E. Krop, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson. The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5165.
Collapse
Affiliation(s)
| | | | | | - Javier Cortés
- 4International Breast Cancer Center, Quironsalud Group, Madrid & Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
6
|
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2019; 20:1226-1238. [PMID: 31402321 DOI: 10.1016/s1470-2045(19)30334-1] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 04/30/2019] [Accepted: 05/01/2019] [Indexed: 01/17/2023]
Abstract
BACKGROUND Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows efficient testing of new combinations before surgery. The activation of the phosphatidylinositol-3-kinase (PI3K) pathway is a known mechanism of resistance to endocrine therapy. Taselisib is an oral, selective PI3K inhibitor with enhanced activity against PIK3CA-mutant cancer cells. The LORELEI trial tested whether taselisib in combination with letrozole would result in an increased proportion of objective responses and pathological complete responses. METHODS In this multicentre, randomised, double-blind, parallel-cohort, placebo-controlled phase 2, study, we enrolled postmenopausal women (aged ≥18 years) with histologically confirmed, oestrogen receptor (ER)-positive, HER2-negative, stage I-III, operable breast cancer, from 85 hospitals in 22 countries worldwide. To be eligible, patients had have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate organ function, and had to have evaluable tumour tissue for PIK3CA genotyping. Patients were randomly assigned (1:1) by means of a permuted block algorithm (block size of four) via an interactive voice or web-based response system, to receive letrozole (2·5 mg/day orally, continuously) with either 4 mg of oral taselisib or placebo (on a 5 days-on, 2 days-off schedule) for 16 weeks, followed by surgery. Randomisation was stratified by tumour size and nodal status. Site staff, patients, and the sponsor were masked to treatment assignment. Coprimary endpoints were the proportion of patients who achieved an objective response by centrally assessed breast MRI and a locally assessed pathological complete response in the breast and axilla (ypT0/Tis, ypN0) at surgery in all randomly assigned patients and in patients with PIK3CA-mutant tumours. Analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02273973, and is closed to accrual. FINDINGS Between Nov 12, 2014, and Aug 12, 2016, 334 participants were enrolled and randomly assigned to receive letrozole and placebo (n=168) or letrozole and taselisib (n=166). Median follow-up was 4·9 months (IQR 4·7-5·1). The study met one of its primary endpoints: the addition of taselisib to letrozole was associated with a higher proportion of patients achieving an objective response in all randomly assigned patients (66 [39%] of 168 patients in the placebo group vs 83 [50%] of 166 in the taselisib group; odds ratio [OR] 1·55, 95% CI 1·00-2·38; p=0·049) and in the PIK3CA-mutant subset (30 [38%] of 79 vs 41 [56%] of 73; OR 2·03, 95% CI 1·06-3·88; p=0·033). No significant differences were observed in pathological complete response between the two groups, either in the overall population (three [2%] of 166 in the taselisib group vs one [1%] of 168 in the placebo group; OR 3·07 [95% CI 0·32-29·85], p=0·37) or in the PIK3CA-mutant cohort (one patient [1%) vs none [0%]; OR not estimable, p=0·48). The most common grade 3-4 adverse events in the taselisib group were gastrointestinal (13 [8%] of 167 patients), infections (eight [5%]), and skin-subcutaneous tissue disorders (eight [5%]). In the placebo group, four (2%) of 167 patients had grade 3 or worse vascular disorders, two (1%) had gastrointestinal disorders, and two (1%) patients had grade 3 or worse infections and infestations. There was no grade 4 hyperglycaemia and grade 3 cases were asymptomatic. Serious adverse events were more common in the taselisib group (eight [5%] patients with infections and seven [4%] with gastrointestinal effects) than in the placebo group (one [1%] patient each with grade 3 postoperative wound and haematoma infection, grade 4 hypertensive encephalopathy, grade 3 acute cardiac failure, and grade 3 breast pain). One death occurred in the taselisib group, which was not considered to be treatment-related. INTERPRETATION The increase in the proportion of patients who achieved an objective response from the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic breast cancer. FUNDING Genentech and F Hoffmann-La Roche.
Collapse
Affiliation(s)
- Cristina Saura
- Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain.
| | | | - Mafalda Oliveira
- Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain
| | | | | | | | - Paolo Nuciforo
- Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain
| | - Alberto Ballestrero
- University of Genoa - Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Policlinico San Martino, Genova; Gruppo Oncologico Italiano di Ricerca Clinica, Genova, Italy
| | - Peter Dubsky
- Medical University of Vienna, Vienna, Austria; Hirslanden Klinik St Anna, Breast Centre, Lucerne, Switzerland
| | - Janine M Lombard
- Breast Cancer Trials Australia New Zealand, University of Newcastle, Newcastle, NSW, Australia
| | - Peter Vuylsteke
- European Organisation for Research and Treatment of Cancer, Breast Cancer Group, CHU Namur, Université Catholique de Louvain, Ottignies-Nouvain-la-Neuve, Belgium
| | | | - Marco Colleoni
- Division of Medical Senology, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico and International Breast Cancer Study Group, Milan, Italy
| | | | - Eva Ciruelos
- SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Monica Fornier
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
| | | | - Aditya Bardia
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | - Yi Shi
- Genentech Inc, South San Francisco, CA, USA
| | - Martine Piccart
- Breast International Group, Brussels, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Michael Gnant
- Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Medical University of Vienna, Vienna, Austria
| | | | | |
Collapse
|
7
|
Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clin Cancer Res 2018; 24:4380-4387. [PMID: 29793946 DOI: 10.1158/1078-0432.ccr-18-0613] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 04/25/2018] [Accepted: 05/19/2018] [Indexed: 11/16/2022]
Abstract
Purpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity. Tumor tissue (if available) was centrally evaluated for PIK3CA mutations. Adverse events (AE) were recorded using NCI-CTCAE v4.0. Tumor response was investigator-determined using RECIST v1.1.Results: Median treatment duration was 4.6 (range: 0.9-40.5) months. All patients experienced ≥1 AE, 30 (50.0%) had grade ≥3 AEs, and 19 (31.7%) experienced 35 serious AEs. Forty-seven of 60 patients had evaluable tissue for central PIK3CA mutation testing [20 had mutations, 27 had no mutation detected (MND)]. In patients with baseline measurable disease, clinical activity was observed in tumors with PIK3CA mutations [best confirmed response rate: 38.5% (5/13; 95% CI, 13.9-68.4); clinical benefit rate (CBR): 38.5% (5/13; 95% CI, 13.9-68.4)], PIK3CA-MND [best confirmed response rate: 14.3% (3/21; 95% CI, 3.0-36.3); CBR: 23.8% (5/21; 95% CI, 8.2-47.2)], and unknown PIK3CA mutation status [best confirmed response rate: 20.0% (2/10; 95% CI, 2.5-55.6); CBR: 30.0% (3/10; 95% CI, 6.7-65.2)].Conclusions: Taselisib plus fulvestrant had clinical activity irrespective of PIK3CA mutation status, with numerically higher objective response rate and CBR in patients with PIK3CA-mutated (vs. -MND) locally advanced or metastatic HER2-negative, HR-positive breast cancer. No new safety signals were reported. A confirmatory phase III trial is ongoing. Clin Cancer Res; 24(18); 4380-7. ©2018 AACR.
Collapse
Affiliation(s)
- Maura N Dickler
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
| | - Cristina Saura
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Donald A Richards
- Medical Oncology, Texas Oncology-Tyler, US Oncology Research, Woodlands, Texas
| | - Ian E Krop
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Andrés Cervantes
- CIBERONC, Medical Oncology Department, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Philippe L Bedard
- Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Manish R Patel
- Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida
| | - Lajos Pusztai
- Yale Cancer Center, Breast Medical Oncology, New Haven, Connecticut
| | - Mafalda Oliveira
- Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | | | - Na Cui
- Genentech, Inc., South San Francisco, California
| | | | | | | | - Jerry Y Hsu
- Genentech, Inc., South San Francisco, California
| | - José Baselga
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York.,Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
8
|
de Azambuja E, Saura C, Nuciforo P, Frantal S, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, Dubsky P, Lombard JM, Vuylsteke P, Castaneda Altamirano C, Sanchez C, Ballestrero A, Colleoni M, Santos Borges G, Ciruelos E, Bardia A, Fornier M, Boer K, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Baselga J, Gnant M. Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd5-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taselisib is an oral, potent, selective inhibitor of Class I PI3-kinase (PI3K) alpha, gamma, and delta isoforms with enhanced activity against PIK3CA mutant cancer cells. LORELEI trial demonstrated a significant improvement in ORR (objective response rate) centrally assessed by MRI with neoadjuvant taselisib plus letrozole compared to letrozole plus placebo in all randomized patients as well as in the PIK3CA mutant cohort (Saura et al, ESMO 2017).
Methods: 334 postmenopausal women with newly diagnosed ER+/HER2-, untreated, Stage I-III operable breast cancer and evaluable tumor tissue for PIK3CA genotyping were randomized (1:1) to receive daily letrozole (2.5 mg) with either taselisib (4 mg on a 5 days on/ 2 days off schedule) or placebo for 16 weeks, followed by surgery. Tumor tissue collection was performed at baseline, week 3 (W3) and at surgery. Secondary objectives included, but were not restricted to, ORR assessed by MRI in patients with PIK3CA wild type (WT) tumors, ORR using alternative methods of tumor assessment (ultrasound, mammogram and clinical breast exam) in all patients and patients with PIK3CA mutant and WT tumors, central assessment of Ki67 at different timepoints (baseline, W3 and surgery), and the centrally derived PEPI score. Central Ki67 was assessed by two independent readers blinded to treatment arms and PIK3CA status (Vall D'Hebron Institute of Oncology, Barcelona).
Results: ORR by centrally assessed MRI was similar in the two treatment arms in patients with PIK3CA WT tumors (45.7 vs 40.4% for taselisib and placebo, respectively). ORR assessed by breast US was also significantly higher with taselisib compared to placebo in all randomized patients and in the PIK3CA mutant cohort. The highest concordance rate between MRI and other imaging modalities was found with breast ultrasound (53.7%). Centrally assessed Ki67 changes are reported in Table 1. Ki67 values decreased from baseline to W3 and from baseline to surgery in both treatment arms. No significant differences in the decrease of Ki67 values between treatment arms were detected. Unplanned analysis of Complete Cell Cycle Arrest (CCCA) at W3 was numerically higher with taselisib than with placebo in all randomized patients (49.6% vs 38.5%) and in the PIK3CA mutant cohort (60.9% vs 47.5%). Due to the variability in timing between the last dose of taselisib (median time 11 days; interquartile range 6-16 days) and tissue collection at surgery, considering the half-life of taselisib of approximately 40 hours, centrally derived PEPI score is not interpretable.
Ki67 proportional changes, %Taselisib + letrozolePlacebo + letrozoleBaseline to W3All patients-83.8-80.4PIK3CA mutant-84.5-79.1PIK3CA WT-82.8-81.1Baseline to surgeryAll patients-75.6-80.5PIK3CA mutant-71.9-79.9PIK3CA WT-78.2-81.2
Conclusion: Among the investigated alternative methods for assessing ORR, breast ultrasound performed similar to MRI. Decrease in the Ki67 values from baseline to W3 and to surgery were observed in both treatment arms. The time interval between taselisib cessation and tissue collection at surgery are being further investigated.
Clinical trial information: NCT02273973
Citation Format: de Azambuja E, Saura C, Nuciforo P, Frantal S, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, Dubsky P, Lombard JM, Vuylsteke P, Castaneda Altamirano C, Sanchez C, Ballestrero A, Colleoni M, Santos Borges G, Ciruelos E, Bardia A, Fornier M, Boer K, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Baselga J, Gnant M. Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-04.
Collapse
Affiliation(s)
- E de Azambuja
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Saura
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Nuciforo
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - S Frantal
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Oliveira
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - D Zardavas
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Jallitsch-Halper
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - L de la Pena
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Dubsky
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - JM Lombard
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - P Vuylsteke
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Castaneda Altamirano
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - C Sanchez
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Ballestrero
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Colleoni
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - G Santos Borges
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - E Ciruelos
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - A Bardia
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Fornier
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - K Boer
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - TR Wilson
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - TJ Stout
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - JY Hsu
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - Y Shi
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Piccart
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - J Baselga
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| | - M Gnant
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Val d'Hebron University Hospital, Institut d'Oncologia, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group, Brussels, Belgium; SOLTI, Barcelona, Spain; Medical University of Vienna, Vienna, Austria; ANZBCTG (Australia New Zealand Breast Cancer Trials Group) and University of Newcastle, Newcastle, Australia; EORTC BCG, CHU UCL Namur, Namur, Belgium; GECOPERU, Lima, Peru; Centro del Cancer, Pontificia Universidad Catolica de Chile, Santiago, Chile; University of Genoa-IRCCS AOU San Martino IST & GOIRC, Genova, Italy; European Institute of Oncology & International Breast Cancer Study Group, Milan, Italy; Cebtro de Novos Tratamentos Itajai, Itajai, Brazil; Hospital Universitario 12 de Octubre, Madrid, Spain; Massachusetts General Hospital & Harvard Medical School, Boston; Memorial Sloan-Kettering Cancer Center, New York; Szent Margit Hospital, Budapest, Hungary; Genentech Inc - R
| |
Collapse
|
9
|
Dickler MN, Saura C, Oliveira M, Richards DA, Krop IE, Cervantes A, Stout TJ, Jin H, Savage HM, Wilson TR, Baselga J. Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-12-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast cancer (BC), with activating mutations of PIK3CA detected in ~35–45% of patients (pts). Acquired mutations in the ESR1 gene, which encodes estrogen receptor α, may be associated with resistance to aromatase inhibitor (AI) therapy. Taselisib is a potent and selective PI3K inhibitor, with greater selectivity against mutant PI3Kα isoforms than wild-type (WT) via a unique mechanism. In phase I studies, taselisib plus fulvestrant had clinical activity and manageable tolerability in pts with HR-positive BC. We report exploratory analyses of PIK3CA and ESR1 from circulating tumor DNA (ctDNA).
Methods:
In this phase II, open-label, single-arm study (PMT4979g; NCT01296555), pts were postmenopausal with HER2-negative, HR-positive locally advanced or metastatic BC and progression or non-response to ≥1 prior endocrine therapy in the adjuvant or metastatic setting. Pts received taselisib (6 mg capsule orally, daily) plus fulvestrant (500 mg intramuscular on Days 1 and 15 of Cycle 1, then Day 1 of each 28-day cycle) until disease progression or unacceptable toxicity. PIK3CA-mutation testing on archival tumor tissue used the cobas® PIK3CA Mutation Test. The Sysmex Inostics' BEAMing Digital PCR platform was used for ctDNA analysis of ESR1 and PIK3CA mutations (pre-dose on Cycle 1, Day 1). Primary endpoints were objective response rate (ORR) and clinical benefit rate (CBR) in all pts and those with PIK3CA mutations. ORR was confirmed complete response (cCR) and confirmed partial response (cPR). CBR was cCR, cPR, or stable disease for ≥6 months. Secondary endpoints included safety, efficacy, pharmacokinetics, and exploratory biomarker analysis.
Results:
60 pts were enrolled. Median age was 61.5 years (range 31–82). In the metastatic setting, pts had received prior chemotherapy (21.7%) and prior hormonal therapy (50.0%). 86.7% of pts had received prior treatment with an AI. 45 pts had PIK3CA mutation status from archival tumor tissue and ctDNA testing; concordance was 86.7% (39/45). ctDNA analysis, vs archival tumor tissue testing, identified 4 pts and 9 pts with PIK3CA mutations from pts with WT and unknown PIK3CA mutation status, respectively.
Based on ctDNA analysis (N=60), 13 pts (21.7%) had mutations in both ESR1 and PIK3CA, 21 pts (35.0%) were 'mutation not detected' (MND) for both genes, 8 (13.3%) had ESR1 mutations and PIK3CA MND, and 18 (30.0%) had ESR1 MND and PIK3CA mutations.
In pts with measurable disease at baseline, confirmed responses (all partial) were: PIK3CA mutation, 38.1% (8/21); PIK3CA MND, 8.7% (2/23); all pts, 22.7% (10/44). CBRs were: PIK3CA mutation, 42.9%; PIK3CA MND, 17.4%; all pts, 29.5%. ORR and CBR from ctDNA analyses were similar to archival tumor tissue data.
Conclusions:
ctDNA analysis identified PIK3CA mutations in pts with previously unknown or WT mutation status from archival tumor tissue; ORR and CBR were similar to those from archival tumor tissue suggesting that PIK3CA mutation testing from ctDNA may be used as a surrogate when tissue is unavailable. 21.7% of pts had mutations in both ESR1 and PIK3CA.
Citation Format: Dickler MN, Saura C, Oliveira M, Richards DA, Krop IE, Cervantes A, Stout TJ, Jin H, Savage HM, Wilson TR, Baselga J. Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-01.
Collapse
Affiliation(s)
- MN Dickler
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - C Saura
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - M Oliveira
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - DA Richards
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - IE Krop
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - A Cervantes
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - TJ Stout
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - H Jin
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - HM Savage
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - TR Wilson
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; US Oncology Research, Woodlands, TX; Dana-Farber Cancer Institute, Boston, MA; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; Genentech Inc., South San Francisco, CA
| |
Collapse
|
10
|
Oliveira M, de Azambuja E, Saura C, Dubsky P, Zardavas D, Fesl C, Bardia A, Soberino J, Ciruelos Gil E, Ng V, Fredrickson J, Stout TJ, Singel SM, Hsu JY, Piccart M, Gnant M, Baselga J. Abstract OT1-03-06: LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/ HER2-negative, early-stage breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot1-03-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taselisib is an orally bioavailable, potent, selective inhibitor of Class I PI3-kinase (PI3K) alpha, gamma, and delta isoforms, with 30-fold less inhibition of the PI3K beta isoform relative to the alpha isoform showing enhanced activity against PIK3CA mutant cancer cell lines. Clinical data have demonstrated confirmed partial responses in patients with PIK3CA mutant breast cancer (BC) treated with single-agent taselisib. Enhanced antitumor activity has been noted when taselisib is combined with either letrozole or fulvestrant in preclinical and Phase Ib clinical studies.
Methods: LORELEI is a Phase II, two-arm, randomized, double-blind, multicenter, study of neoadjuvant letrozole and taselisib versus letrozole and placebo in postmenopausal women with newly diagnosed ER+/HER2-, untreated, Stage I-III operable BC. Other eligibility criteria include tumor size 2 cm by magnetic resonance imaging (MRI), ECOG PS 0-1, and evaluable tumor tissue for PIK3CA genotyping. Patients treated with anti-diabetic drugs are not eligible. Patients are randomized (1:1) to receive continuous letrozole (2.5 mg) with either taselisib (4 mg on a 5 days on/ 2 days off schedule) or placebo for 16 weeks, followed by surgery. Stratification is based on tumor size and nodal status. The co-primary endpoints are overall objective response rate (ORR) by centrally assessed breast MRI via modified RECIST criteria and pathologic complete response (pCR) rate in breast and axilla at time of surgery in all randomized patients and PIK3CA mutant patients. Secondary endpoints include ORR by centrally-assessed MRI and pCR rate in PIK3CA wild-type patients. The sample size was calculated to detect an absolute percentage increase of 24% in ORR with 80% power and an absolute percentage increase of 18% in pCR rate. An interim safety analysis will be conducted by an Independent Data Monitoring Committee. As of 1st Jun 2015, 54 of the 330 patients have been enrolled, and global enrollment is ongoing (clinicaltrials.gov NCT02273973).
Contact information:
Reference Study ID Numbers: GO28888/BIG-3-13/SOLTI 1205/ABCSG 38
Phone: 888-662-6728 (US Only)
Email Address: global.rochegenentechtrials@roche.com
Citation Format: Oliveira M, de Azambuja E, Saura C, Dubsky P, Zardavas D, Fesl C, Bardia A, Soberino J, Ciruelos Gil E, Ng V, Fredrickson J, Stout TJ, Singel SM, Hsu JY, Piccart M, Gnant M, Baselga J. LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/ HER2-negative, early-stage breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-03-06.
Collapse
Affiliation(s)
- M Oliveira
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - E de Azambuja
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - C Saura
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - P Dubsky
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - D Zardavas
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - C Fesl
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - A Bardia
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - J Soberino
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - E Ciruelos Gil
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - V Ng
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - J Fredrickson
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - TJ Stout
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - SM Singel
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - JY Hsu
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - M Piccart
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - M Gnant
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| | - J Baselga
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Jules Bordet Institute, Brussels, Belgium; Breast Data Centre at the Jules Bordet Institute, Brussels, Belgium; Medical University of Vienna, Vienna, Austria; ABCSG Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Breast International Group (BIG aisbl), Brussels, Belgium; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 12 de Octubre University Hospital, Madrid, Spain; Genentech, Inc., South San Francisco, CA; Memorial Sloan-Kettering Cancer Center, NY, NY
| |
Collapse
|
11
|
Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC. Erratum to “Discovery of XL413, a potent and selective CDC7 inhibitor” [Bioorg. Med. Chem. Lett. 22 (2012) 3727–3731]. Bioorg Med Chem Lett 2012. [DOI: 10.1016/j.bmcl.2012.06.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR, Le DT, Mac M, Parks JJ, Qian F, Rodriquez M, Stout TJ, Till JH, Won KA, Wu X, Yakes FM, Yu P, Zhang W, Zhao Y, Lamb P, Nuss JM, Xu W. The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2012; 22:4979-85. [PMID: 22765894 DOI: 10.1016/j.bmcl.2012.06.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Revised: 06/06/2012] [Accepted: 06/11/2012] [Indexed: 10/28/2022]
Abstract
Variously substituted indolin-2-ones were synthesized and evaluated for activity against KDR, Flt-1, FGFR-1 and PDGFR. Extension at the 5-position of the oxindole ring with ethyl piperidine (compound 7i) proved to be the most beneficial for attaining both biochemical and cellular potencies. Further optimization of 7i to balance biochemical and cellular potencies with favorable ADME/ PK properties led to the identification of 8h, a compound with a clean CYP profile, acceptable pharmacokinetic and toxicity profiles, and robust efficacy in multiple xenograft tumor models.
Collapse
Affiliation(s)
- Moon H Kim
- Exelixis, 210 E. Grand Avenue, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KSM, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2007; 66:11100-5. [PMID: 17145850 DOI: 10.1158/0008-5472.can-06-2554] [Citation(s) in RCA: 202] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a novel triarylimidazole that selectively inhibits Raf kinases with more potency towards B-Raf than c-Raf. Crystallographic analysis revealed that SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously reported mechanism of action of the multi-kinase inhibitor, BAY43-9006. Malignant cells expressing oncogenic B-Raf show selective inhibition of mitogen-activated protein kinase activation, proliferation, transformation, and tumorigenicity when exposed to SB-590885, whereas other cancer cell lines and normal cells display variable sensitivities or resistance to similar treatment. These studies support the validation of oncogenic B-Raf as a target for cancer therapy and provide the first evidence of a correlation between the expression of oncogenic BRAF alleles and a positive response to a selective B-Raf inhibitor.
Collapse
Affiliation(s)
- Alastair J King
- Department of Oncology, MMPD CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lougheed JC, Chen RH, Mak P, Stout TJ. Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1. J Biol Chem 2004; 279:44039-45. [PMID: 15308621 DOI: 10.1074/jbc.m406703200] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
ACK1 is a multidomain non-receptor tyrosine kinase that is an effector of the Cdc42 GTPase. Members of the ACK family have a unique domain ordering and are the only tyrosine kinases known to interact with Cdc42. In contrast with many protein kinases, ACK1 has only a modest increase in activity upon phosphorylation. We have solved the crystal structures of the human ACK1 kinase domain in both the unphosphorylated and phosphorylated states. Comparison of these structures reveals that ACK1 adopts an activated conformation independent of phosphorylation. Furthermore, the unphosphorylated activation loop is structured, and its conformation resembles that seen in activated tyrosine kinases. In addition to the apo structure, complexes are also presented with a non-hydrolyzable nucleotide analog (adenosine 5'-(beta,gamma-methylenetriphosphate)) and with the natural product debromohymenialdisine, a general inhibitor of many protein kinases. Analysis of these structures reveals a typical kinase fold, a pre-organization into the activated conformation, and an unusual substrate-binding cleft.
Collapse
Affiliation(s)
- Julie C Lougheed
- Exelixis, Incorporated, South San Francisco, California 94083-0511, USA
| | | | | | | |
Collapse
|
15
|
Abstract
Structural biology is an invaluable tool in modern drug discovery, providing key insights into the interactions of small-molecule drugs with their protein targets. As in many aspects of the drug discovery process, significant synergies can be realized in structural biology by the contemporaneous pursuit of many target proteins from a single structural and functional class. We will review some of those synergies here using the example of the protein kinases--an important class of drug targets that has recently been the subject of intensive study. We conclude by discussing some of the technical advances in X-ray crystallography that have enabled implementation of high-throughput structural biology as applied to drug lead optimization.
Collapse
Affiliation(s)
- T J Stout
- Exelixis Inc., 170 Harbor Way, S. San Francisco, CA 94080, USA
| | | | | |
Collapse
|
16
|
Abstract
The crystal structure of PfPK5, a cyclin-dependent kinase from Plasmodium falciparum, is the first CDK structure determined from a nonhuman source and represents a potential new target for anti-malarial drug development.
Collapse
Affiliation(s)
- Linda S Brinen
- Sandler Center for Basic Parasitic Disease Research, Department of Cellular and Molecular Pharmacology, University of California at San Francisco, San Francisco, CA 94143, USA
| | | |
Collapse
|
17
|
|
18
|
Tapiolas DM, Roman M, Fenical W, Stout TJ, Clardy J. Octalactins A and B: cytotoxic eight-membered-ring lactones from a marine bacterium, Streptomyces sp. J Am Chem Soc 2002. [DOI: 10.1021/ja00012a048] [Citation(s) in RCA: 105] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
|
20
|
|
21
|
Elbaum D, Porco JAJ, Stout TJ, Clardy J, Schreiber SL. Stereochemical and Conformational Effects on the Cycloaromatization of Dynemicin A-Related Molecules. J Am Chem Soc 2002. [DOI: 10.1021/ja00106a025] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
|
23
|
|
24
|
Holt DA, Luengo JI, Yamashita DS, Oh HJ, Konialian AL, Yen HK, Rozamus LW, Brandt M, Bossard MJ, Levy MA, Eggleston DS, Liang J, Schultz LW, Stout TJ, Clardy J. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12. J Am Chem Soc 2002. [DOI: 10.1021/ja00075a008] [Citation(s) in RCA: 177] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Sugawara F, Strobel S, Strobel G, Larsen RD, Berglund DL, Gray G, Takahashi N, Coval SJ, Stout TJ, Clardy J. The structure and biological activity of cercosporamide from Cercosporidium henningsii. J Org Chem 2002. [DOI: 10.1021/jo00003a002] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
|
27
|
Trischman JA, Tapiolas DM, Jensen PR, Dwight R, Fenical W, McKee TC, Ireland CM, Stout TJ, Clardy J. Salinamides A and B: anti-inflammatory depsipeptides from a marine streptomycete. J Am Chem Soc 2002. [DOI: 10.1021/ja00081a042] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
|
29
|
|
30
|
|
31
|
Abstract
Serpins exhibit a range of physiological roles and can contribute to certain disease states dependent on their various conformations. Understanding the mechanisms of the large-scale conformational reorganizations of serpins may lead to a better understanding of their roles in various cardiovascular diseases. We have studied the serpin, plasminogen activator inhibitor 1 (PAI-1), in both the active and the latent state and found that anionic halide ions may play a role in the active-to-latent structural transition. Crystallographic analysis of a stable mutant form of active PAI-1 identified an anion-binding site between the central beta-sheet and a small surface domain. A chloride ion was modeled in this site, and its identity was confirmed by soaking crystals in a bromide-containing solution and calculating a crystallographic difference map. The anion thus located forms a 4-fold ligated linchpin that tethers the surface domain to the central beta-sheet into which the reactive center loop must insert during the active-to-latent transition. Timecourse experiments measuring active PAI-1 stability in the presence of various halide ions showed a clear trend for stabilization of the active form with F(-) > Cl(-) > Br(-) >> I(-). We propose that the "stickiness" of this pin (i.e., the electronegativity of the anion) contributes to the energetics of the active-to-latent transition in the PAI-1 serpin.
Collapse
Affiliation(s)
- T J Stout
- MetaXen, South San Francisco, CA 94080, USA.
| | | | | | | |
Collapse
|
32
|
Costi PM, Rinaldi M, Tondi D, Pecorari P, Barlocco D, Ghelli S, Stroud RM, Santi DV, Stout TJ, Musiu C, Marangiu EM, Pani A, Congiu D, Loi GA, La Colla P. Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. J Med Chem 1999; 42:2112-24. [PMID: 10377217 DOI: 10.1021/jm9900016] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A new set of phthalein derivatives stemming from the lead compound, phenolphthalein, were designed to specifically complement structural features of a bacterial form of thymidylate synthase (Lactobacillus casei, LcTS) versus the human TS (hTS) enzyme. The new compounds were screened for their activity and their specificity against TS enzymes from different species, namely, L. casei (LcTS), Pneumocystis carinii (PcTS), Cryptococcus neoformans (CnTS), and human thymidylate synthase (hTS). Apparent inhibition constants (Ki) for all the compounds against LcTS were determined, and inhibition factors (IF, ratio between the initial rates of the enzymatic reaction in the presence and absence of each inhibitor) against each of the four TS species were measured. A strong correlation was found between the two activity parameters, IF and Ki, and therefore the simpler IF was used as a screening factor in order to accelerate biological evaluation. Compounds 5b, 5c, 5ba, and 6bc showed substantial inhibition of LcTS while remaining largely inactive against hTS, illustrating for the first time remarkable species specificity among TSs. Due to sequence homology between the enzymes, several compounds also showed high activity and specificity for CnTS. In particular, 3-hydroxy-3-(3-chloro-4-hydroxyphenyl)-6-nitro-1H, 3H-naphtho[1,8-c,d]pyran-1-one (6bc) showed an IF < 0.04 for CnTS (Ki = 0.45 microM) while remaining inactive in the hTS assay at the maximum solubility concentration of the compound (200 microM). In cell culture assays most of the compounds were found to be noncytotoxic to human cell lines but were cytotoxic against several species of Gram-positive bacteria. These results are consistent with the enzymatic assays. Intriguingly, several compounds also had selective activity against Cr. neoformans in cell culture assay. In general, the most active and selective compounds against the Gram-positive bacteria were those designed and found in the enzyme assay to be specific for LcTS versus hTS. The original lead compound was least selective against most of the cell lines tested. To our knowledge these compounds are the first TS inhibitors selective for bacterial TS with respect to hTS.
Collapse
Affiliation(s)
- P M Costi
- Dipartimento Scienze Farmaceutiche and Dipartimento Scienze Chimiche, Università di Modena e Reggio Emilia, Via Campi 183, 41100 Modena, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Stout TJ, Tondi D, Rinaldi M, Barlocco D, Pecorari P, Santi DV, Kuntz ID, Stroud RM, Shoichet BK, Costi MP. Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 1999; 38:1607-17. [PMID: 9931028 DOI: 10.1021/bi9815896] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Thymidylate synthase is an attractive target for antiproliferative drug design because of its key role in the synthesis of DNA. As such, the enzyme has been widely targeted for anticancer applications. In principle, TS should also be a good target for drugs used to fight infectious disease. In practice, TS is highly conserved across species, and it has proven to be difficult to develop inhibitors that are selective for microbial TS enzymes over the human enzyme. Using the structure of TS from Lactobacillus casei in complex with the nonsubstrate analogue phenolphthalein, inhibitors were designed to take advantage of features of the bacterial enzyme that differ from those of the human enzyme. Upon synthesis and testing, these inhibitors were found to be up to 40-fold selective for the bacterial enzyme over the human enzyme. The crystal structures of two of these inhibitors in complex with TS suggested the design of further compounds. Subsequent synthesis and testing showed that these second-round compounds inhibit the bacterial enzyme at sub-micromolar concentrations, while the human enzyme was not inhibited at detectable levels (selectivities of 100-1000-fold or greater). Although these inhibitors share chemical similarities, X-ray crystal structures reveal that the analogues bind to the enzyme in substantially different orientations. Site-directed mutagenesis experiments suggest that the individual inhibitors may adopt multiple configurations in their complexes with TS.
Collapse
Affiliation(s)
- T J Stout
- Department of Biochemistry, University of California, San Francisco 94143-0448, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Unlike all other organisms studied to date, Bacillus subtilis expresses two different thymidylate synthases: bsTS-A and bsTS-B. bsTS-A displays enhanced enzymatic and structural thermal stability uncharacteristic of most TSs. Despite the high level of TS conservation across most species, bsTS-A shares low sequence identity (<40%) with the majority of TSs from other organisms. This TS and the TSs from Lactococcus lactis and phage Phi3T-to which it is most similar-have been of interest for some time since, by structure-based sequence alignment, they appear to lack several key residues shown by mutagenesis to be essential to enzymatic function [Greene, P. J., Yu, P. L., Zhao, J., Schiffer, C. A., and Santi, D. (1994) Protein Sci. 3, 1114-6]. In addition, bsTS-A demonstrates specific activity 2-3-fold higher than TS from Lactobacillus casei or Escherichia coli. We have solved the crystal structure of this unusual TS in four crystal forms to a maximum resolution of 1.7 A. Each of these crystal forms contains either one or two noncrystallographically related dimers. Stabilization of the beta-sheet dimer interface through a dramatic architecture of buttressed internal salt bridges maintains the structural integrity of bsTS-A at elevated temperatures. Melting curves of TSs from L. casei and E. coli are compared to that of TS-A from B. subtilis and correlated with numbers of hydrogen bonds, salt bridges, and the numbers of interactions localized to the dimer interface. Analysis of this structure will shed light on the conservation of function across diversity of sequence, as well as provide insights into the thermal stabilization of a highly conserved enzyme.
Collapse
Affiliation(s)
- T J Stout
- Department of Biochemistry, School of Medicine, University of California, San Francisco 94143-0448, USA
| | | | | | | |
Collapse
|
35
|
Sage CR, Michelitsch MD, Stout TJ, Biermann D, Nissen R, Finer-Moore J, Stroud RM. D221 in thymidylate synthase controls conformation change, and thereby opening of the imidazolidine. Biochemistry 1998; 37:13893-901. [PMID: 9753479 DOI: 10.1021/bi9810510] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In thymidylate synthase (TS), the invariant residue Asp-221 provides the only side chain that hydrogen bonds to the pterin ring of the cofactor, 5,10-methylene-5,6,7,8-tetrahydrofolate. All mutants of D221 except cysteine abolish activity. We have determined the crystal structures of two ternary complexes of the Escherichia coli mutant D221N. In a complex with dUMP and the antifolate 10-propargyl-5,8-dideazafolate (CB3717), dUMP is covalently bound to the active site cysteine, as usual. CB3717, which has no imidazolidine ring, is also bound in the usual productive orientation, but is less ordered than in wild-type complexes. The side chain of Asn-221 still hydrogen bonds to N3 of the quinazoline ring of CB3717, which must be in the enol form. In contrast, the structure of D221N with 5-fluoro-dUMP and 5,10-methylene-5,6,7, 8-tetrahydrofolate shows the cofactor bound in two partially occupied, nonproductive binding sites. In both binding modes, the cofactor has a closed imidazolidine ring and adopts the solution conformation of the unbound cofactor. In one of the binding sites, the pterin ring is turned around such that Asn-221 hydrogen bonds to the unprotonated N1 instead of the protonated N3 of the cofactor. This orientation blocks the conformational change required for forming covalent ternary complexes. Taken together, the two crystal structures suggest that the hydrogen bond between the side chain of Asp-221 and N3 of the cofactor is most critical during the early steps of cofactor binding, where it enforces the correct orientation of the pterin ring. Proper orientation of the cofactor appears to be a prerequisite for opening the imidazolidine ring prior to formation of the covalent steady-state intermediate in catalysis.
Collapse
Affiliation(s)
- C R Sage
- Department of Biochemistry and Biophysics, University of California at San Francisco 94143-0448, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
BACKGROUND Enzymes have evolved to recognise their target substrates with exquisite selectivity and specificity. Whether fragments of the substrate--perhaps never available to the evolving enzyme--are bound in the same manner as the parent substrate addresses the fundamental basis of specificity. An understanding of the relative contributions of individual portions of ligand molecules to the enzyme-binding interaction may offer considerable insight into the principles of substrate recognition. RESULTS We report 12 crystal structures of Escherichia coli thymidylate synthase in complexes with available fragments of the substrate (dUMP), both with and without the presence of a cofactor analogue. The structures display considerable fidelity of binding mode and interactions. These complexes reveal several interesting features: the cofactor analogue enhances the localisation of substrate and substrate fragments near the reactive thiol; the ribose moiety reduces local disorder through additional specific enzyme-ligand interactions; the pyrimidine has multiple roles, ranging from stereospecificity to mechanistic competence; and the glycosidic linkage has an important role in the formation of a covalent attachment between substrate and enzyme. CONCLUSIONS The requirements of ligand-protein binding can be understood in terms of the binding of separate fragments of the ligand. Fragments which are subsystems of the natural substrate for the enzyme confer specific contributions to the binding affinity, orientation or electrostatics of the enzymatic mechanism. This ligand-binding analysis provides a complementary method to the more prevalent approaches utilising site-directed mutagenesis. In addition, these observations suggest a modular approach for rational drug design utilising chemical fragments.
Collapse
Affiliation(s)
- T J Stout
- Department of Biochemistry, School of Medicine, University of California, San Francisco 94143-0448, USA
| | | | | |
Collapse
|
37
|
Murata T, Kimura H, Sakamoto T, Osusky R, Spee C, Stout TJ, Hinton DR, Ryan SJ. Ocular gene therapy: experimental studies and clinical possibilities. Ophthalmic Res 1997; 29:242-51. [PMID: 9323715 DOI: 10.1159/000268022] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The Human Genome Project will identify, map and sequence all 50,000-100,000 human genes and will provide the tools to determine the genetic basis of both common and rare diseases. Understanding the genetic basis of human disease will allow for the development of highly specific drugs and for replacement of the altered gene through gene therapy. Gene therapy may also be used to introduce a new function into cells with resulting therapeutic benefit. Genes may be delivered into cells in vitro or in vivo utilizing viral or nonviral vectors. Viral vectors which have been used include retroviruses, adenoviruses, adeno-associated viruses and herpes viruses. Ocular disorders with the greatest potential for benefit of gene therapy at the current time include hereditary ocular diseases, including retinitis pigmentosa, tumors such as retinoblastoma or melanoma, and acquired proliferative and neovascular retinal disorders. We have demonstrated the feasibility of ocular gene therapy in a rabbit model of proliferative vitreoretinopathy, using retroviral vectors containing the herpes simplex virus thymidine kinase 'suicide' gene. Although in vivo transduction efficiency is low, the strong bystander effect results in prominent killing of proliferating cells in this model leading to inhibition of disease. In the future, gene therapy has the potential for the replacement of defective gene products or introduction of new gene products into ocular cells. The selection of appropriate target genes and cells will be critical, as will the development of a methodology for safe, targeted gene transfer.
Collapse
Affiliation(s)
- T Murata
- Doheny Eye Institute, Los Angeles, CA 90033, USA
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Sage CR, Rutenber EE, Stout TJ, Stroud RM. An essential role for water in an enzyme reaction mechanism: the crystal structure of the thymidylate synthase mutant E58Q. Biochemistry 1996; 35:16270-81. [PMID: 8973201 DOI: 10.1021/bi961269r] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A water-mediated hydrogen bond network coordinated by glutamate 60(58) appears to play an important role in the thymidylate synthase (TS) reaction mechanism. We have addressed the role of glutamate 60(58) in the TS reaction by cocrystalizing the Escherichia coli TS mutant E60(58)Q with dUMP and the cofactor analog CB3717 and have determined the X-ray crystal structure to 2.5 A resolution with a final R factor of 15.2% (Rfree = 24.0%). Using difference Fourier analysis, we analyzed directly the changes that occur between wild-type and mutant structures. The structure of the mutant enzyme suggests that E60(58) is not required to properly position the ligands in the active site and that the coordinated hydrogen bond network has been disrupted in the mutant, providing an atomic resolution explanation for the impairment of the TS reaction by the E60(58)Q mutant and confirming the proposal that E60(58) coordinates this conserved hydrogen bond network. The structure also provides insight into the role of specific waters in the active site which have been suggested to be important in the TS reaction. Finally, the structure shows a unique conformation for the cofactor analog, CB3717, which has implications for structure-based drug design and sheds light on the controversy surrounding the previously observed enzymatic nonidentity between the chemically identical monomers of the TS dimer.
Collapse
Affiliation(s)
- C R Sage
- Department of Biochemistry and Biophysics, University of California, San Francisco 94143-0448, USA
| | | | | | | |
Collapse
|
39
|
Stout TJ, Stroud RM. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition. Structure 1996; 4:67-77. [PMID: 8805515 DOI: 10.1016/s0969-2126(96)00010-x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Thymidylate synthase (TS) is critical to DNA synthesis as it catalyzes the rate limiting step in the only biosynthetic pathway for deoxythymidine monophosphate (dTMP) production. TS is therefore an important target for anti-proliferative and anti-cancer drug design. The TS enzymatic mechanism involves the reductive methylation of the substrate, deoxyuridine monophosphate (dUMP), by transfer of a methylene group from the co-factor, methylenetetrahydrofolate (CH2H4folate), resulting in the production of deoxythymidine monophosphate (dTMP) and dihydrofolate (H2folate). Previous drug design efforts based on co-factor analogues have produced good inhibitors of TS, but poor bioavailability and toxicity have limited their usefulness. BW1843U89, a folate analogue, is a recently developed compound which is an exceptionally strong inhibitor (Ki = 0.09 nM), has good bioavailability and in clinical trials thus far has not demonstrated significant toxicity. RESULTS We report the crystal structure of E. coli TS in ternary complex with dUMP and BW1843U89 at 2.0 A resolution. Although the benzoquinazoline ring system of the inhibitor binds to TS in much the same manner as previously determined for H2folate and CB3717, the larger size of the ligand is accommodated by the enzyme through a local distortion of the active site, that is not strictly conserved in both monomers in the asymmetric unit. Several conserved waters that had been previously implicated in mechanistic roles have been displaced. CONCLUSIONS BW1843U89 forms a ternary complex with dUMP and completes with CH2H4 folate at the active site. Inhibition of TS by BW1843U89 shows four unique aspects in its mechanism of action. BW1843U89 prevents the Michael addition of dUMP to Cys146, in contrast to the mechanisms implicated from crystallography of other quinazoline based inhibitors; displaces a catalytic water from the active site; reorders a peptide loop (Leu72-Trp83) in the active site; and is unique amongst the antifolates in inactivating TS at a stoichiometric ratio of one molecule per TS dimer. Thus, it exploits the principles of negative cooperativity that are increasingly being recognized in the catalytic mechanism of the enzyme per se. The structure suggests that this 'half-the-sites' effect is catalytic and not related to ligand binding. Therefore BW1843U89 is both a competitive inhibitor (at the binding site) and a non-competitive inhibitor at the other site.
Collapse
Affiliation(s)
- T J Stout
- Department of Biochemistry and Biophysics, School of Medicine, University of California at San Francisco 94143-0448, USA
| | | |
Collapse
|
40
|
|
41
|
Kimura Y, Nishibe M, Nakajima H, Hamasaki T, Shigemitsu N, Sugawara F, Stout TJ, Clardy J. Emeniveol; A new pollen growth inhibitor from the fungus, Emericella nivea. Tetrahedron Lett 1992. [DOI: 10.1016/s0040-4039(00)60913-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
|
43
|
Abstract
The structures of four new drimane-type sesquiterpenes 1–4 produced in liquid cultures of the fairy ring fungus, Marasmiusoreades, have been determined by a combination of chemical and spectroscopic methods. The structure assigned to one of these sesquiterpenes (1) has been confirmed by an X-ray crystallographic study. An unprecedented feature of all four sesquiterpenes is the biosynthetic elaboration of C8–C12 and C15 of the drimane skeleton to a dioxabicyclooctane moiety. In addition, two of the sesquiterpenes possess an uncommon α orientation of the hydroxyl groups at C3. Keywords: sesquiterpenes, fungal metabolites, drimanes, fairy ring mushroom, crystal structure.
Collapse
|
44
|
Robert A, Stout TJ, Dale JE. Production by secretagogues of duodenal ulcers in the rat. Gastroenterology 1970; 59:95-102. [PMID: 5426995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|